CatalYm Advances Visugromab into Phase 2/3 Development for Cancer Cachexia with First Patient Dosed

AI Briefing

• – CatalYm's visugromab shows promise in Phase 2/3 trial for cancer cachexia
• – First patient dosed in VINCIT trial, a randomized, double-blind, placebo-controlled study
• – Study aims to enroll 518 patients with cancer-associated cachexia